Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo

References

• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177 - 82; http://dx.doi.org/10.1126/science.3798106; PMID: 3798106
   PubMed Web of Science ®Google Scholar
• Barbacci EG, Guarino BC, Stroh JG, Singleton DH, Rosnack KJ, Moyer JD, et al. The structural basis for the specificity of epidermal growth factor and heregulin binding. J Biol Chem 1995; 270:9585 - 9; http://dx.doi.org/10.1074/jbc.270.16.9585; PMID: 7721889
   PubMed Web of Science ®Google Scholar
• Leu M, Bellmunt E, Schwander M, Fariñas I, Brenner HR, Müller U. Erbb2 regulates neuromuscular synapse formation and is essential for muscle spindle development. Development 2003; 130:2291 - 301; http://dx.doi.org/10.1242/dev.00447; PMID: 12702645
   PubMed Web of Science ®Google Scholar
• Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987; 84:7159 - 63; http://dx.doi.org/10.1073/pnas.84.20.7159; PMID: 2890160
   PubMed Web of Science ®Google Scholar
• Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006; 24:5658 - 63; http://dx.doi.org/10.1200/JCO.2006.07.0250; PMID: 17102066
   PubMed Web of Science ®Google Scholar
• Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005; 92:1253 - 60; http://dx.doi.org/10.1038/sj.bjc.6602499; PMID: 15785739
   PubMed Web of Science ®Google Scholar
• Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006; 24:2376 - 85; http://dx.doi.org/10.1200/JCO.2005.03.4827; PMID: 16710036
   PubMed Web of Science ®Google Scholar
• Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15:65 - 71; PMID: 16328035
   PubMed Web of Science ®Google Scholar
• Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig 1996; 3:99 - 105; http://dx.doi.org/10.1016/1071-5576(96)00001-9; PMID: 8796816
   PubMedGoogle Scholar
• Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21:3995 - 4004; http://dx.doi.org/10.1128/MCB.21.12.3995-4004.2001; PMID: 11359907
   PubMed Web of Science ®Google Scholar
• Yokoi A, McCrudden KW, Huang J, Kim ES, Soffer SZ, Frischer JS, et al. Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol Rep 2003; 10:1271 - 4; PMID: 12883692
   PubMed Web of Science ®Google Scholar
• Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003; 102:964 - 71; http://dx.doi.org/10.1182/blood-2002-12-3738; PMID: 12689940
   PubMed Web of Science ®Google Scholar
• Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999; 59:1592 - 8; PMID: 10197634
   PubMed Web of Science ®Google Scholar
• Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ. Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 1994; 5:89 - 97; http://dx.doi.org/10.1016/0955-2235(94)90019-1; PMID: 7515293
   PubMedGoogle Scholar
• Kim DW, Huamani J, Fu A, Hallahan DE. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64:38 - 46; http://dx.doi.org/10.1016/j.ijrobp.2005.02.008; PMID: 16377414
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317 - 28; http://dx.doi.org/10.1016/S1535-6108(04)00083-2; PMID: 15093539
   PubMed Web of Science ®Google Scholar
• de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005; 69:Suppl 3 46 - 56; http://dx.doi.org/10.1159/000088483; PMID: 16301835
   PubMed Web of Science ®Google Scholar
• Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, et al. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007; 179:472 - 82; PMID: 17579068
   PubMed Web of Science ®Google Scholar
• Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem.
   Google Scholar
• Srinivasan M, Gienapp IE, Stuckman SS, Rogers CJ, Jewell SD, Kaumaya PTP, et al. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol 2002; 169:2180 - 8; PMID: 12165548
   PubMed Web of Science ®Google Scholar
• Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127 - 37; http://dx.doi.org/10.1016/S1535-6108(02)00097-1; PMID: 12204533
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443 - 6; http://dx.doi.org/10.1038/74704; PMID: 10742152
   PubMed Web of Science ®Google Scholar
• Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1995; 3:21 - 6; http://dx.doi.org/10.1016/1074-7613(95)90155-8; PMID: 7621075
   PubMed Web of Science ®Google Scholar
• Wary KK, Thakker GD, Humtsoe JO, Yang J. Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol Cancer 2003; 2:25; http://dx.doi.org/10.1186/1476-4598-2-25; PMID: 12904264
   PubMedGoogle Scholar
• Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004; 9:Suppl 1 43 - 9; http://dx.doi.org/10.1634/theoncologist.9-suppl_1-43; PMID: 15178815
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11393 - 8; http://dx.doi.org/10.1073/pnas.172398299; PMID: 12177445
   PubMed Web of Science ®Google Scholar
• Carpenito C, Davis PD, Dougherty ST, Dougherty GJ. Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2002; 54:1473 - 8; http://dx.doi.org/10.1016/S0360-3016(02)03921-4; PMID: 12459373
   PubMed Web of Science ®Google Scholar
• Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood 2003; 101:1316 - 23; http://dx.doi.org/10.1182/blood-2002-07-2184; PMID: 12406876
   PubMed Web of Science ®Google Scholar
• Monsky WL, Mouta Carreira C, Tsuzuki Y, Gohongi T, Fukumura D, Jain RK. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 2002; 8:1008 - 13; PMID: 11948107
   PubMed Web of Science ®Google Scholar
• Stern DF, Kamps MP. EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J 1988; 7:995 - 1001; PMID: 3261240
   PubMed Web of Science ®Google Scholar
• Wada T, Qian XL, Greene MI. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 1990; 61:1339 - 47; http://dx.doi.org/10.1016/0092-8674(90)90697-D; PMID: 1973074
   PubMed Web of Science ®Google Scholar
• Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011; 286:13612 - 25; http://dx.doi.org/10.1074/jbc.M110.216812; PMID: 21321115
   PubMed Web of Science ®Google Scholar
• Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going?. Br J Cancer 2004; 90:1 - 7; http://dx.doi.org/10.1038/sj.bjc.6601401; PMID: 14710197
   PubMed Web of Science ®Google Scholar
• Sundaram R, Lynch MP, Rawale SV, Sun Y, Kazanji M, Kaumaya PT. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem 2004; 279:24141 - 51; http://dx.doi.org/10.1074/jbc.M313210200; PMID: 15060075
   PubMed Web of Science ®Google Scholar
• Söll R, Beck-Sickinger AG. On the synthesis of orexin A: a novel one-step procedure to obtain peptides with two intramolecular disulphide bonds. J Pept Sci 2000; 6:387 - 97; http://dx.doi.org/10.1002/1099-1387(200008)6:8<387::AID-PSC267>3.0.CO;2-M; PMID: 10969868
   PubMed Web of Science ®Google Scholar
• Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165:5133 - 42; PMID: 11046045
   PubMed Web of Science ®Google Scholar
• Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003; 170:4242 - 53; PMID: 12682258
   PubMed Web of Science ®Google Scholar
• Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 2003; 171:2637 - 43; PMID: 12928417
   PubMed Web of Science ®Google Scholar
• Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 2001; 276:22892 - 900; http://dx.doi.org/10.1074/jbc.M011647200; PMID: 11303022
   PubMed Web of Science ®Google Scholar
• Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 2007; 26:328 - 33; http://dx.doi.org/10.1097/01.pgp.0000235065.31301.3e; PMID: 17581420
   PubMed Web of Science ®Google Scholar